cardiovascular disease

Vitamin D3 (Cholecalciferol) is a naturally occurring form of vitamin D that, after metabolic activation, can induce cell differentiation and cancer cell proliferation. It can also be used to establish kidney stone models.

BI-1935 is an inhibitor of soluble epoxide hydrolase (sEH). For diseases related to cardiovascular disease.

Sirtuin modulator 2 (N-(3-(imidazo[2,1-b]thiazol-6-yl)phenyl)-2-methoxybenzamide) exhibits antidiabetic, anti-inflammatory and antitumor activities.

Moexipril hydrochloride (Moexipril HCl) is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart failure.

Regaloside C, a glycerol glucoside isolated from the Lilium genus, exhibits notable anti-inflammatory properties.

KDM4-IN-4 (compound 47) is a potent inhibitor of histone lysine demethylase 4 (KDM4), with a binding constant of approximately 80 μM for the KDM4A-Tudor domain. It inhibits H3K4Me3 binding to the Tudor domain in cellular contexts with an EC50 value of 105 μM, holding potential for anticancer research applications [1].

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

Apelin agonist 1 is an orally available APJ receptor agonist with an EC50 value of 3.2 nM. Apelin agonist 1 is used in the study of cardiovascular disease.

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

Tiapamil hydrochloride (Ro 11-1781 hydrochloride) is a calcium channel blocker with antihypertensive activity and may be used in the study of angina and cardiovascular disease.

GP2-114 is a catecholamine motility mimetic that produces current-dependent cardiovascular effects when administered via transdermal iontophoresis and can be used to study coronary artery disease (CAD).

AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeable trifluoromethyl ketone analog of arachidonic acid and a potent, selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). By blocking the production of arachidonate and 12-hydroxyeicosatetraenoic acid in calcium ionophore-challenged platelets, AACOCF3 hinders their synthesis. Additionally, AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets, making it promising for cardiovascular disease research.

Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascular disease and can be used to study atherosclerosis and thrombosis.

Aprikalim (RP 52891) is an adenosine triphosphate potassium channel (KATP) opener that protects against nerve damage in a rabbit model of spinal cord ischemia.Aprikalim inhibits vasoconstriction and inhibits the elevation of [Ca2+]i during myocardial paralysis, and can be used to study cardiovascular disease.

Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb/IIIa antagonist for the study of cardiovascular disease.

FPL-62129 is a calcium channel antagonist and a novel angiotensin-converting enzyme inhibitor with vasodilator activity for the study of cardiovascular disease.

Gue1654 is a selective OXE-R inhibitor that attenuates coronary artery ligation-induced ischemic myocardial injury and cardiomyocyte oxygen/glucose deprivation-induced injury in mice through activation of BCAT1.Gue1654 inhibits OXE-R-inhibited protein kinase C-ε (PKC-ε)/nuclear factor κB (NF-κB) signaling and apoptosis in cardiomyocytes. Gue1654 can be used to study cardiovascular disease.

Pomisartan (BIBR-363) is a small molecule angiotensin type 1 receptor (AT1R) antagonist that is used in the treatment of cardiovascular disease, studying heart failure and hypertensio

Ro 09-0680, a compound derived from Salvia miltiorrhiza, is a potent inhibitor of collagen-induced platelet aggregation in rabbits with potential anti-inflammatory activity for the study of cardiovascular disease.

Atecegatran TFA is often used as an anticoagulant and can be used to treat cardiovascular disease.

CP-642931 (Sorbitol dehydrogenase-IN-1) is an orally active and highly potent sorbitol dehydrogenase inhibitor for the study of diabetes and cardiovascular disease.

Eldacimibe (WAY-ACA-147) is an ACAT2 inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, study of atherosclerosis and hypercholesterolemia.

Indolidan (LY 195115) induces cardiovascular and adrenal hyperplastic lesions in Fischer 344 rats. Indolidan increases the risk of cardiovascular disease.